Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of Allocetra-OTS with PIPAC for peritoneal metastases
MOH_2022-06-08_010545Phase 2Completed
- Sponsor
- Enlivex Therapeutics
- Start
- May 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Allocetra in peritoneal carcinomatosis (PC) (4 cohorts), sponsored by Enlivex Therapeutics. Started May 2022; status: completed.
02
Drugs
Allocetra
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on MOH_2022-06-08_010545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-08_010545.